Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 11, 2023

Prognostic Significance of HER2-Low Status in HR+/HER2− Advanced Breast Cancer Treated With CDK4/6 Inhibitors

NPJ breast cancer


Additional Info

NPJ breast cancer
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
NPJ Breast Cancer 2023 Apr 17;9(1)27, E Zattarin, D Presti, L Mariani, C Sposetti, R Leporati, A Menichetti, C Corti, C Benvenuti, G Fucà, R Lobefaro, F Ligorio, L Provenzano, A Vingiani, M Del Vecchio, G Griguolo, M Sirico, O Bernocchi, A Marra, P Zagami, E Agostinetto, F Jacobs, P Di Mauro, A Esposito, CA Giorgi, L Lalli, L Boldrini, PPB Giacchetti, AC Schianca, V Guarneri, R Pedersini, A Losurdo, A Zambelli, D Generali, C Criscitiello, G Curigliano, G Pruneri, F de Braud, MV Dieci, C Vernieri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading